Lantheus Holdings plans to acquire Life Molecular Imaging for an upfront payment of $350 million and up to an additional $400 million in potential earn-out and milestone payments.
Life Molecular is a subsidiary of Life Healthcare Group, and is dedicated to developing PET radiopharmaceutical diagnostics, Lantheus said. The company expects the purchase to boost its near- and long-term growth profile and establish a commercial Alzheimer's disease product line with the addition of Neuraceq (florbetaben F18). (Neuraceq is a globally approved diagnostic agent indicated for PET imaging of the brain to estimate amyloid-beta neuritic plaque density in adult patients with cognitive impairment who are being evaluated for Alzheimer's disease and other causes of cognitive decline, according to the firm.)
The deal builds on Lantheus' June 2024 acquisition of the global rights to LMI's clinical-stage radiotherapeutic and radiodiagnostic pair, Lu-177 DOTA-RM2 and 68Ga-DOTA-RM2, it said.
